Back to Search Start Over

Spider Venom Peptide Pn3a Inhibition of Primary Afferent High Voltage-Activated Calcium Channels.

Authors :
McArthur JR
Munasinghe NR
Finol-Urdaneta RK
Adams DJ
Christie MJ
Source :
Frontiers in pharmacology [Front Pharmacol] 2021 Jan 28; Vol. 11, pp. 633679. Date of Electronic Publication: 2021 Jan 28 (Print Publication: 2020).
Publication Year :
2021

Abstract

Despite potently inhibiting the nociceptive voltage-gated sodium (Na <subscript>v</subscript> ) channel, Na <subscript>v</subscript> 1.7, µ -theraphotoxin Pn3a is antinociceptive only upon co-administration with sub-therapeutic opioid agonists, or by itself at doses >3,000-fold greater than its Na <subscript>v</subscript> 1.7 IC <subscript> 50 </subscript> by a yet undefined mechanism. Na <subscript>v</subscript> channels are structurally related to voltage-gated calcium (Ca <subscript>v</subscript> ) channels, Ca <subscript>v</subscript> 1 and Ca <subscript>v</subscript> 2. These channels mediate the high voltage-activated (HVA) calcium currents ( I <subscript> Ca </subscript> ) that orchestrate synaptic transmission in nociceptive dorsal root ganglion (DRG) neurons and are fine-tuned by opioid receptor (OR) activity. Using whole-cell patch clamp recording, we found that Pn3a (10 µM) inhibits ∼55% of rat DRG neuron HVA- I <subscript> Ca </subscript> and 60-80% of Ca <subscript>v</subscript> 1.2, Ca <subscript>v</subscript> 1.3, Ca <subscript>v</subscript> 2.1, and Ca <subscript>v</subscript> 2.2 mediated currents in HEK293 cells, with no inhibition of Ca <subscript>v</subscript> 2.3. As a major DRG I <subscript> Ca </subscript> component, Ca <subscript>v</subscript> 2.2 inhibition by Pn3a ( IC <subscript> 50 </subscript> = 3.71 ± 0.21 µM) arises from an 18 mV hyperpolarizing shift in the voltage dependence of inactivation. We observed that co-application of Pn3a and µ-OR agonist DAMGO results in enhanced HVA- I <subscript> Ca </subscript> inhibition in DRG neurons whereas co-application of Pn3a with the OR antagonist naloxone does not, underscoring HVA channels as shared targets of Pn3a and opioids. We provide evidence that Pn3a inhibits native and recombinant HVA Ca <subscript>v</subscript> s at previously reportedly antinociceptive concentrations in animal pain models. We show additive modulation of DRG HVA- I <subscript> Ca </subscript> by sequential application of low Pn3a doses and sub-therapeutic opioids ligands. We propose Pn3a's antinociceptive effects result, at least in part, from direct inhibition of HVA- I <subscript> Ca </subscript> at high Pn3a doses, or through additive inhibition by low Pn3a and mild OR activation.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 McArthur, Munasinghe, Finol-Urdaneta, Adams and Christie.)

Details

Language :
English
ISSN :
1663-9812
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Academic Journal
Accession number :
33584315
Full Text :
https://doi.org/10.3389/fphar.2020.633679